Status
Conditions
Treatments
About
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
4,000 participants in 1 patient group
Loading...
Central trial contact
Marie BENHAMMANI-GODARD; Jeremie Zerbit, PharmD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal